ASX - By Stock
|
PER |
Re:
For General Information
|
|
HoldiIgnatz
|
3.5K |
1.0M |
6 |
13/12/23 |
13/12/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
6
|
|
ASX - By Stock
|
PER |
Re:
Ann: Annual General Meeting Presentation
|
|
HoldiIgnatz
|
81 |
21K |
3 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
81
|
21K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
HoldiIgnatz
|
45 |
11K |
0 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
45
|
11K
|
0
|
|
ASX - By Stock
|
PER |
Re:
James Garner AKA JG
|
|
HoldiIgnatz
|
190 |
50K |
1 |
15/08/23 |
15/08/23 |
ASX - By Stock
|
190
|
50K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Trading Halt
|
|
HoldiIgnatz
|
158 |
45K |
1 |
17/07/23 |
17/07/23 |
ASX - By Stock
|
158
|
45K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Some insights into backend work with ATL-1102
|
|
HoldiIgnatz
|
14 |
3.6K |
0 |
20/06/23 |
20/06/23 |
ASX - By Stock
|
14
|
3.6K
|
0
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
HoldiIgnatz
|
3.5K |
1.0M |
1 |
23/05/23 |
23/05/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
1
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
HoldiIgnatz
|
3.5K |
1.0M |
2 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
2
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
HoldiIgnatz
|
3.5K |
1.0M |
2 |
23/01/23 |
23/01/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
2
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
HoldiIgnatz
|
3.5K |
1.0M |
2 |
28/12/22 |
28/12/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics CEO announces retirement
|
|
HoldiIgnatz
|
204 |
68K |
2 |
08/12/22 |
08/12/22 |
ASX - By Stock
|
204
|
68K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics CEO announces retirement
|
|
HoldiIgnatz
|
204 |
68K |
0 |
30/11/22 |
30/11/22 |
ASX - By Stock
|
204
|
68K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics CEO announces retirement
|
|
HoldiIgnatz
|
204 |
68K |
0 |
28/11/22 |
28/11/22 |
ASX - By Stock
|
204
|
68K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: Application for quotation of securities - ANP
|
|
HoldiIgnatz
|
44 |
10K |
6 |
24/11/22 |
24/11/22 |
ASX - By Stock
|
44
|
10K
|
6
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
HoldiIgnatz
|
3.5K |
1.0M |
0 |
21/11/22 |
21/11/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
0
|
|
ASX - By Stock
|
PER |
Re:
ANP Value
|
|
HoldiIgnatz
|
328 |
91K |
2 |
11/11/22 |
11/11/22 |
ASX - By Stock
|
328
|
91K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Combo Data
|
|
HoldiIgnatz
|
99 |
27K |
1 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
99
|
27K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Dosing commenced in DMD combination therapy study
|
|
HoldiIgnatz
|
91 |
30K |
3 |
20/09/22 |
20/09/22 |
ASX - By Stock
|
91
|
30K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: ATL1102 Revised Plans accelerate reporting of unblinded data
|
|
HoldiIgnatz
|
351 |
87K |
5 |
08/09/22 |
08/09/22 |
ASX - By Stock
|
351
|
87K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Ann: Long Covid-19 Collaboration Outcomes Presentation
|
|
HoldiIgnatz
|
228 |
86K |
0 |
22/08/22 |
22/08/22 |
ASX - By Stock
|
228
|
86K
|
0
|
|
ASX - By Stock
|
PER |
Re:
atl1102 in the Box seat re DMD. Sarepta fails .
|
|
HoldiIgnatz
|
114 |
30K |
4 |
15/02/22 |
15/02/22 |
ASX - By Stock
|
114
|
30K
|
4
|
|